APP and Alzheimer disease: In its preventive application, this strategy would only delay but not prevent the disease (because the AβPP-independent C100/C99 production pathway is activated at levels of iAβ below the T1 threshold), and in the treatment of AD, the progression of the disease would be slowed down but not arrested.